Alnylam Pharmaceuticals Share Price (NASDAQ: ALNY)

$454.29

▲

-13.26

(-2.84%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Alnylam Pharmaceuticals Stock chart to analyse performance

Alnylam Pharmaceuticals stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$454.29
Today's High:$467.29
$454.29
0.0%
Downside
Day's Volatility :2.78%
Upside
2.78%
52 Weeks Low:$205.87
52 Weeks High:$467.15
$454.29
54.68%
Downside
52 Weeks Volatility :55.93%
Upside
2.75%

Alnylam Pharmaceuticals Stock Returns

Period	Alnylam Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	60.9%	5.0%	0.0%
6 Months	87.51%	-6.4%	0.0%
1 Year	71.21%	-11.5%	0.0%
3 Years	111.21%	4.5%	-7.7%

Alnylam Pharmaceuticals, Inc. Key Stats

Check Alnylam Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$467.55
Open	$466.87
Today's High	$467.29
Today's Low	$454.29
Market Capitalization	$60.1B
Today's Volume	$760.1K
52 Week High	$467.29
52 Week Low	$205.87
Revenue TTM	$2.5B
EBITDA	$-123.7M
Earnings Per Share (EPS)	$-2.47
Profit Margin	-12.96%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-257.83%

Stock Returns calculator for Alnylam Pharmaceuticals Stock including INR - Dollar returns

The Alnylam Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Alnylam Pharmaceuticals investment value today

Current value as on today

₹1,68,090

Returns

₹68,090

(+68.09%)

Returns from Alnylam Pharmaceuticals Stock

₹63,808 (+63.81%)

Dollar Returns*

₹4,281 (+4.28%)

Indian investors sentiment towards Alnylam Pharmaceuticals Stock

69.05%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Investment in Alnylam Pharmaceuticals Shares from India has grown by 69.05% over the past 30 days, indicating increased transactional activity.

239%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Alnylam Pharmaceuticals Stock from India on INDmoney has increased by 239% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Alnylam Pharmaceuticals, Inc.

Name
Holdings %
Name
Holdings %
Capital World Investors
12.82%
FMR Inc
11.68%
Vanguard Group Inc
10.14%
BlackRock Inc
7.29%
Capital Research Global Investors
5.49%
Regeneron Pharmaceuticals Inc
3.39%

Analyst Recommendation on Alnylam Pharmaceuticals Stock

Rating

Trend

Buy

70%Buy

29%Hold

0%Sell

Based on 34 Wall street analysts offering stock ratings for Alnylam Pharmaceuticals(by analysts ranked 0 to 5 stars)

Alnylam Pharmaceuticals Share Price Target

What analysts predicted

Downside of 6.53%

Target:

$424.64

Current:

$454.29

Alnylam Pharmaceuticals share price target is $424.64, a slight Downside of 6.53% compared to current price of $454.29 as per analysts' prediction.

Alnylam Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, ALNY stock has moved up by 43.5%
Increasing Revenue
Alnylam Pharmaceuticals, Inc. has experienced consistent revenue growth over the last four quarters. The revenue increased from $500.91 million to $773.68 million. This represents an average increase of 13.0% per quarter.
Decreasing Net Profit
Alnylam Pharmaceuticals, Inc. has seen a decline in its net profit over the last two quarters. The net profit decreased from -$57.47 million to -$66.27 million, which means the company is losing more money. This represents an average decrease of 15.3% in net profit each quarter.

Alnylam Pharmaceuticals, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$219.8M	↑ 193.36%
Net Income	$-886.1M	↑ 16.37%
Net Profit Margin	-403.24%	↑ 613.34%

	FY20	Y/Y Change
Revenue	$492.9M	↑ 124.28%
Net Income	$-858.3M	↓ 3.14%
Net Profit Margin	-174.15%	↑ 229.09%

	FY21	Y/Y Change
Revenue	$844.3M	↑ 71.31%
Net Income	$-852.8M	↓ 0.64%
Net Profit Margin	-101.01%	↑ 73.14%

	FY22	Y/Y Change
Revenue	$1.0B	↑ 22.88%
Net Income	$-1.1B	↑ 32.64%
Net Profit Margin	-109.04%	↓ 8.03%

	FY23	Y/Y Change
Revenue	$1.8B	↑ 76.23%
Net Income	$-440.2M	↓ 61.08%
Net Profit Margin	-24.08%	↑ 84.96%

	FY24	Y/Y Change
Revenue	$2.2B	↑ 22.97%
Net Income	$-278.2M	↓ 36.82%
Net Profit Margin	-12.37%	↑ 11.71%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$494.3M	↑ 12.42%
Net Income	$-65.9M	↓ 52.18%
Net Profit Margin	-13.34%	↑ 18.01%

	Q2 FY24	Q/Q Change
Revenue	$659.8M	↑ 33.48%
Net Income	$-16.9M	↓ 74.39%
Net Profit Margin	-2.56%	↑ 10.78%

	Q3 FY24	Q/Q Change
Revenue	$500.9M	↓ 24.08%
Net Income	$-111.6M	↑ 560.61%
Net Profit Margin	-22.27%	↓ 19.71%

	Q4 FY24	Q/Q Change
Revenue	$593.2M	↑ 18.42%
Net Income	$-83.8M	↓ 24.92%
Net Profit Margin	-14.12%	↑ 8.15%

	Q1 FY25	Q/Q Change
Revenue	$594.2M	↑ 0.17%
Net Income	$-57.5M	↓ 31.38%
Net Profit Margin	-9.67%	↑ 4.45%

	Q2 FY25	Q/Q Change
Revenue	$773.7M	↑ 30.21%
Net Income	$-66.3M	↑ 15.31%
Net Profit Margin	-8.57%	↑ 1.1%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$194.7M	↑ 166.31%

	FY20	Y/Y Change
Profit	$414.8M	↑ 113.06%

	FY21	Y/Y Change
Profit	$704.1M	↑ 69.75%

	FY22	Y/Y Change
Profit	$868.6M	↑ 23.36%

	FY23	Y/Y Change
Profit	$1.5B	↑ 74.75%

	FY24	Y/Y Change
Profit	$1.9B	↑ 26.81%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$428.4M	↑ 21.05%

	Q2 FY24	Q/Q Change
Profit	$591.2M	↑ 38.0%

	Q3 FY24	Q/Q Change
Profit	$415.0M	↓ 29.8%

	Q4 FY24	Q/Q Change
Profit	$490.3M	↑ 18.15%

	Q1 FY25	Q/Q Change
Profit	$523.1M	↑ 6.69%

	Q2 FY25	Q/Q Change
Profit	$630.7M	↑ 20.57%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-278.4M	↓ 50.51%
Investing Cash Flow	$-417.7M	↓ 253.03%
Financing Cash Flow	$823.2M	↑ 1157.35%

	FY20	Y/Y Change
Operating Cash Flow	$-615.0M	↑ 120.87%
Investing Cash Flow	$-435.5M	↑ 4.27%
Financing Cash Flow	$995.0M	↑ 20.87%

	FY21	Y/Y Change
Operating Cash Flow	$-641.7M	↑ 4.35%
Investing Cash Flow	$-273.3M	↓ 37.25%
Financing Cash Flow	$1.2B	↑ 25.34%

	FY22	Y/Y Change
Operating Cash Flow	$-541.3M	↓ 15.65%
Investing Cash Flow	$169.4M	↓ 161.97%
Financing Cash Flow	$425.8M	↓ 65.86%

	FY23	Y/Y Change
Operating Cash Flow	$104.2M	↓ 119.24%
Investing Cash Flow	$-336.4M	↓ 298.61%
Financing Cash Flow	$172.1M	↓ 59.57%

	FY24	Y/Y Change
Operating Cash Flow	$-8.3M	↓ 107.98%
Investing Cash Flow	$-116.8M	↓ 65.26%
Financing Cash Flow	$294.2M	↑ 70.89%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-81.5M	↑ 173.59%
Investing Cash Flow	$-67.6M	↓ 71.9%
Financing Cash Flow	$28.9M	↓ 26.3%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$124.2M	↓ 252.31%
Investing Cash Flow	$33.9M	↓ 150.19%
Financing Cash Flow	$131.5M	↑ 354.83%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$43.7M	↓ 64.8%
Investing Cash Flow	$-30.3M	↓ 189.13%
Financing Cash Flow	$102.8M	↓ 21.86%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-94.7M	↓ 316.58%
Investing Cash Flow	$-52.9M	↑ 74.91%
Financing Cash Flow	$31.0M	↓ 69.83%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-118.3M	↑ 24.99%
Investing Cash Flow	$113.8M	↓ 315.02%
Financing Cash Flow	$44.1M	↑ 42.22%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$153.7M	↓ 229.93%
Investing Cash Flow	$-141.4M	↓ 224.27%
Financing Cash Flow	$53.8M	↑ 21.94%

Alnylam Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Alnylam Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Alnylam Pharmaceuticals, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Alnylam Pharmaceuticals, Inc.	43.34%	87.51%	71.21%	111.21%	254.29%
Regeneron Pharmaceuticals, Inc.	4.5%	-16.14%	-50.12%	-0.77%	0.56%
Beone Medicines Ltd	6.48%	21.45%	61.97%	78.16%	32.24%
Vertex Pharmaceuticals Incorporated	-16.69%	-17.5%	-17.43%	36.53%	48.58%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91
Regeneron Pharmaceuticals, Inc.	14.9	14.9	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.01	28.01	0.58	18.06	0.23	0.13	NA	67.02

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	254.29%	NA	-12.96%
Regeneron Pharmaceuticals, Inc.	Buy	$62.6B	0.56%	14.9	31.37%
Beone Medicines Ltd	NA	$37.6B	32.24%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.1B	48.58%	28.01	31.86%

Alnylam Pharmaceuticals Dividend announcements

Alnylam Pharmaceuticals Earnings
Alnylam Pharmaceuticals’s price-to-earnings ratio stands at None

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Organization	Alnylam Pharmaceuticals
Employees	2230
CEO	Dr. Yvonne L. Greenstreet M.B.A., M.D.
Industry	Health Technology

Key Management of Alnylam Pharmaceuticals, Inc.

Name	Title
Dr. Yvonne L. Greenstreet M.B.A., M.D.	CEO & Director
Dr. Phillip A. Sharp Ph.D.	Co-Founder, Member of the Scientific Advisory Board
Mr. Jeffrey V. Poulton M.B.A.	CFO & Executive VP
Dr. Kevin Joseph Fitzgerald Ph.D.	Executive VP, Chief Scientific Officer and Head of Early Research & Early Development
Dr. Pushkal P. Garg M.D.	Chief Medical Officer, EVP of Development & Medical Affairs and Chief Research & Dev. Officer
Mr. Tolga Tanguler M.B.A.	Executive VP & Chief Commercial Officer
Mr. Timothy J. Maines	Chief Technical Operations & Quality Officer
Mr. Piyush Sharma J.D.	Chief Ethics & Compliance Officer
Mr. Robert W. Hesslein Esq., J.D.	Executive VP, Chief Legal Officer & Corporate Secretary
Ms. Christine Regan Akinc	Chief Corporate Communications Officer

Important FAQs about investing in ALNY Stock from India :

What is Alnylam Pharmaceuticals share price today?

Alnylam Pharmaceuticals share price today is $454.29 as on August 23, 2025 at 1:29 AM IST at the close of the market. Alnylam Pharmaceuticals share today touched a day high of $467.29 and a low of $454.29.

What is the 52 week high and 52 week low for Alnylam Pharmaceuticals share?

Alnylam Pharmaceuticals share touched a 52 week high of $467.15 and a 52 week low of $205.87. Alnylam Pharmaceuticals stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $454.29, lower by 2.75% versus the 52 week high.

How to invest in Alnylam Pharmaceuticals Stock (ALNY) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Alnylam Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alnylam Pharmaceuticals Shares that will get you 0.0033 shares as per Alnylam Pharmaceuticals share price of $454.29 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Alnylam Pharmaceuticals Stock (ALNY) from India?

Indian investors can start investing in Alnylam Pharmaceuticals (ALNY) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Alnylam Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Alnylam Pharmaceuticals share’s latest price of $454.29 as on August 23, 2025 at 1:29 AM IST, you will get 0.0220 shares of Alnylam Pharmaceuticals. Learn more about fractional shares .

What are the returns that Alnylam Pharmaceuticals has given to Indian investors in the last 5 years?

Alnylam Pharmaceuticals stock has given 254.29% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?